Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protalix BioTherapeutics's quarterly market cap
increased
from Dec. 2025 (€119.83 Mil) to Mar. 2026 (€149.06 Mil) and
increased
from Mar. 2026 (€149.06 Mil) to Jun. 2026 (€162.76 Mil).
Protalix BioTherapeutics's annual market cap
increased
from Dec. 2023 (€118.11 Mil) to Dec. 2024 (€131.41 Mil) but then
declined
from Dec. 2024 (€131.41 Mil) to Dec. 2025 (€119.83 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Protalix BioTherapeutics's Enterprise Value for Today is €135.63 Mil.
Protalix BioTherapeutics (FRA:PBDA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Protalix BioTherapeutics Market Cap Related Terms
Protalix BioTherapeutics Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PBDA vs GLSI, DTIL, NERV: Market Cap Comparison
For the Biotechnology subindustry, Protalix BioTherapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protalix BioTherapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Protalix BioTherapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics (FRA:PBDA) has a Market Cap of €162.78 Mil as of Aug. 19, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Protalix BioTherapeutics and its competitors. According to the industry distribution chart, Protalix BioTherapeutics ranks #630 out of 1422 companies in the Biotechnology industry, placing it in the top 44.3%.
Is Protalix BioTherapeutics' Market Cap too high?
Protalix BioTherapeutics' current Market Cap is €162.78 Mil. Based on the distribution chart, Protalix BioTherapeutics ranks #630 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Protalix BioTherapeutics has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' Market Cap compare to GLSI and DTIL?
According to the Biotechnology industry distribution chart, Protalix BioTherapeutics ranks #630 out of 1422 companies for Market Cap. This puts Protalix BioTherapeutics in the upper half of its industry. The industry median Market Cap is 118.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 118.87, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Protalix BioTherapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 118.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protalix BioTherapeutics's current Market Cap is €162.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (FRA:PBDA) is currently considered Fairly Valued. The stock's GF Value™ is €1.89, compared to a current price of €2.00 — trading 5.8% above its estimated fair value. The current Market Cap is €162.78 Mil. Protalix BioTherapeutics' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Protalix BioTherapeutics (FRA:PBDA), the current Market Cap is €162.78 Mil as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protalix BioTherapeutics (FRA:PBDA) Overvalued in 2026?
Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued.
The current stock price of €2.00 is trading 5.8% above its estimated GF Value™ of €1.89.
GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.
Key valuation signals for FRA:PBDA:
Market Cap: €162.78 Mil
GF Value™: €1.89 vs. price of €2.00 (5.8% above fair value)
No single metric tells the full story. See the FRA:PBDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
56GF Score
Get the complete analysis for FRA:PBDA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PBDA has been successfully added to your 
